With box warnings

Without box warnings

Branded

Generic

4 results

aldurazyme
(laronidase)
Genzyme Corporation
Usage: ALDURAZYME® is indicated for treating adults and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), as well as those with moderate to severe symptoms of the Scheie form. Its safety for mildly affected Scheie patients and CNS effects are not established.
elaprase
(idursulfase)
Takeda Pharmaceuticals America, Inc.
Usage: ELAPRASE is indicated for treating Hunter syndrome (MPS II) in patients 5 years and older, improving walking capacity. In patients aged 16 months to 5 years, it reduces spleen volume, but its effects on disease symptoms are unclear. Safety and efficacy for those under 16 months remain unestablished.
naglazyme
(galsulfase)
BioMarin Pharmaceutical Inc.
Usage: NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) and has demonstrated effectiveness in improving walking and stair-climbing capacity.
vimizim
(elosulfase alfa)
BioMarin Pharmaceutical Inc.
Usage: Vimizim (elosulfase alfa) is indicated for the treatment of Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome.

Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme class drugs

aldurazyme